Safety and Effectiveness of Routine Tenecteplase Use in a Large Telestroke Network.

IF 1.2 4区医学 Q4 CLINICAL NEUROLOGY

Neurologist Pub Date : 2026-05-01 DOI:10.1097/NRL.0000000000000657

Arpan Dutta, Arnab Sarkar, Subhadeep Gupta, Uddalak Chakraborty, Chayan Mondal, Soumozit Banerjee, Deep Das, Alapan Paul, Snehansu S Samanta, Sujoy Sarkar, Susanta Chakrabarty, Chinmoy Barik, Diptak Bhowmick, Sanat K Jatua, Snehasis Das, Samiran Misra, Biswajit Ray, Phalguni Das, Binod Das, Barun Das, Avijit Naskar, Dhiraj Roy, Bichitra Biswas, Amit K Das, Dipanjan Das, Aniruddha Sarkar, Rabiul Alam, Kaushik Pal, Kalyan K Das, Samir K Datta, Somnath Ghosh, Sishir K Naskar, Prasenjit Majumdar, Amit K Ghosh, Souvik Sen, Soumya Ghosh, Nitai C Mandal, Subhransu S Datta, Asit K Biswas, Swapan Saren, Manimoy Bandopadhyay, Biman K Ray

{"title":"Safety and Effectiveness of Routine Tenecteplase Use in a Large Telestroke Network.","authors":"Arpan Dutta, Arnab Sarkar, Subhadeep Gupta, Uddalak Chakraborty, Chayan Mondal, Soumozit Banerjee, Deep Das, Alapan Paul, Snehansu S Samanta, Sujoy Sarkar, Susanta Chakrabarty, Chinmoy Barik, Diptak Bhowmick, Sanat K Jatua, Snehasis Das, Samiran Misra, Biswajit Ray, Phalguni Das, Binod Das, Barun Das, Avijit Naskar, Dhiraj Roy, Bichitra Biswas, Amit K Das, Dipanjan Das, Aniruddha Sarkar, Rabiul Alam, Kaushik Pal, Kalyan K Das, Samir K Datta, Somnath Ghosh, Sishir K Naskar, Prasenjit Majumdar, Amit K Ghosh, Souvik Sen, Soumya Ghosh, Nitai C Mandal, Subhransu S Datta, Asit K Biswas, Swapan Saren, Manimoy Bandopadhyay, Biman K Ray","doi":"10.1097/NRL.0000000000000657","DOIUrl":null,"url":null,"abstract":"Objectives: Tenecteplase is an emerging alternative to Alteplase in the management of acute ischemic stroke (AIS). Strong evidence supports the noninferiority of Tenecteplase compared with Alteplase in AIS. Tenecteplase is often preferred due to its affordability, ease of administration, and superior recanalization potential in large vessel occlusion. In this study, we report on the safety and effectiveness of routine Tenecteplase use in a large telestroke network in eastern India.Methods: This retrospective observational study analyzes patient records collected under the Swasthya Ingit Telestroke Program in West Bengal, India. AIS patients who underwent thrombolysis in the 41 hospitals of the Swasthya Ingit Telestroke Network between January 2022 and December 2024 were included in this study. Patients receiving Tenecteplase were compared with those receiving Alteplase. The percentage of patients achieving a good outcome (defined as a score of 0 to 2 on the modified Rankin scale at 90 d), the rate of symptomatic intracranial hemorrhage, and all-cause mortality within 3 months were the main parameters of comparison between the 2 thrombolytic agents.Results: A total of 1526 patients were included in this study. Of these, 1389 patients received Tenecteplase, while 137 patients received Alteplase. Mixed-effects multivariable logistic regression did not demonstrate any association between the thrombolytic agent used and favorable outcomes [Tenecteplase odds ratio: 1.03 (95% CI: 0.56-1.87), P =0.93], symptomatic intracranial hemorrhage [Tenecteplase odds ratio: 0.63 (95% CI: 0.21-1.87), P =0.41], or all-cause mortality [Tenecteplase odds ratio: 0.54 (95% CI: 0.24-1.24), P =0.15].Conclusion: The routine use of Tenecteplase for managing acute ischemic stroke appears to be safe and effective in real-world practice.","PeriodicalId":49758,"journal":{"name":"Neurologist","volume":" ","pages":"70-73"},"PeriodicalIF":1.2000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/NRL.0000000000000657","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Tenecteplase is an emerging alternative to Alteplase in the management of acute ischemic stroke (AIS). Strong evidence supports the noninferiority of Tenecteplase compared with Alteplase in AIS. Tenecteplase is often preferred due to its affordability, ease of administration, and superior recanalization potential in large vessel occlusion. In this study, we report on the safety and effectiveness of routine Tenecteplase use in a large telestroke network in eastern India.

Methods: This retrospective observational study analyzes patient records collected under the Swasthya Ingit Telestroke Program in West Bengal, India. AIS patients who underwent thrombolysis in the 41 hospitals of the Swasthya Ingit Telestroke Network between January 2022 and December 2024 were included in this study. Patients receiving Tenecteplase were compared with those receiving Alteplase. The percentage of patients achieving a good outcome (defined as a score of 0 to 2 on the modified Rankin scale at 90 d), the rate of symptomatic intracranial hemorrhage, and all-cause mortality within 3 months were the main parameters of comparison between the 2 thrombolytic agents.

Results: A total of 1526 patients were included in this study. Of these, 1389 patients received Tenecteplase, while 137 patients received Alteplase. Mixed-effects multivariable logistic regression did not demonstrate any association between the thrombolytic agent used and favorable outcomes [Tenecteplase odds ratio: 1.03 (95% CI: 0.56-1.87), P =0.93], symptomatic intracranial hemorrhage [Tenecteplase odds ratio: 0.63 (95% CI: 0.21-1.87), P =0.41], or all-cause mortality [Tenecteplase odds ratio: 0.54 (95% CI: 0.24-1.24), P =0.15].

Conclusion: The routine use of Tenecteplase for managing acute ischemic stroke appears to be safe and effective in real-world practice.

查看原文本刊更多论文

在大型中风网络中常规使用替奈普酶的安全性和有效性。

目的：替奈普酶是急性缺血性卒中（AIS）治疗中替代阿替普酶的一种新兴药物。强有力的证据支持在AIS中与阿替普酶相比，替奈普酶的非劣效性。Tenecteplase通常是首选，因为它价格合理，易于给药，并且在大血管闭塞中具有优越的再通潜力。在这项研究中，我们报告了在印度东部的一个大型中风网络中常规使用Tenecteplase的安全性和有效性。方法：本回顾性观察性研究分析了印度西孟加拉邦Swasthya Ingit卒中项目收集的患者记录。该研究纳入了2022年1月至2024年12月期间在Swasthya Ingit卒中网络的41家医院接受溶栓治疗的AIS患者。将接受替奈普酶治疗的患者与接受阿替普酶治疗的患者进行比较。获得良好预后的患者百分比（定义为90 d时改良Rankin评分0 ~ 2分）、症状性颅内出血发生率和3个月内全因死亡率是两种溶栓药物比较的主要参数。结果：本研究共纳入1526例患者。其中，1389名患者接受了Tenecteplase， 137名患者接受了Alteplase。混合效应多变量logistic回归未显示使用溶栓剂与良好结局[替奈替普酶优势比：1.03 (95% CI: 0.56-1.87)， P=0.93]、症状性颅内出血[替奈替普酶优势比：0.63 (95% CI: 0.21-1.87)， P=0.41]或全因死亡率[替奈替普酶优势比：0.54 (95% CI: 0.24-1.24)， P=0.15]之间存在任何关联。结论：临床上常规应用替奈普酶治疗急性缺血性脑卒中是安全有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurologist 医学-临床神经学

CiteScore

1.90

自引率

0.00%

发文量

151

审稿时长

2 months

期刊介绍： The Neurologist publishes articles on topics of current interest to physicians treating patients with neurological diseases. The core of the journal is review articles focusing on clinically relevant issues. The journal also publishes case reports or case series which review the literature and put observations in perspective, as well as letters to the editor. Special features include the popular "10 Most Commonly Asked Questions" and the "Patient and Family Fact Sheet," a handy tear-out page that can be copied to hand out to patients and their caregivers.